Entity

Time filter

Source Type

Vandœuvre-lès-Nancy, France

Genetic or epidemiological tests can be used to determine a person’s risk of developing a new or recurrent familial breast cancer. Not only cognitive but factors such as anxiety influence understanding of and confidence in the results, decision-making, and satisfaction with testing. Emotion plays a strong role in the perception of risk information but is frequently underemphasized in the medical communication. We discuss and put into context several reflections that explore the whole setting and course of life after being labeled as a person at high risk. © 2014, Springer-Verlag France. Source


Hannoun-Levi J.-M.,Center Antoine Lacassagne | Hannoun-Levi J.-M.,University of Nice Sophia Antipolis | Peiffert D.,Institute Of Cancerologie Of Lorraine
Cancer/Radiotherapie | Year: 2013

For more than a century, brachytherapy has been a treatment of choice for delivering a high dose in a small volume. However, over the past 15years, this irradiation technique has stalled. Even so, brachytherapy allows the delivery of the right dose at the right place by dispensing with target volume motion and repositioning. The evolution of brachytherapy can be based on a road-map including at least the following three points: the acquisition of clinical evidence, teaching and valuation of the procedures. The evolution of brachytherapy will be also impacted by technological considerations (end of the production of low dose rate 192 iridium wires). Regarding the evolution toward a personalized treatment, brachytherapy of the future should take its place as a partner of other modern external beam radiation techniques, be performed by experimented actors (physicians, physicists, technicians, etc.) who received adequate training, and be valued in proportion to the delivered medical service. © 2013 Société française de radiothérapie oncologique (SFRO). Source


Gangler A.,Institute Of Cancerologie Of Louest | Lesur A.,Institute Of Cancerologie Of Lorraine | Dalenc F.,Institute Claudius Regaud
Oncologie | Year: 2016

The growing number of breast cancer survivors challenges healthcare organizations, particularly oncology specialty and primary care providers. Currently, in France, the follow-up care is based on detection of recurrences, of second primary contralateral breast cancer, of long-term treatment sequelae, in addition to psychosocial consequences of cancer and its treatment. This review will discuss the evidence base and intents of breast cancer survivorship care plans (CSCPs) as a wellness model for cancer survivors in clinical setting, mainly providing health promotion recommendations such as regular exercise. The CPCPs involve multidisciplinary approach and patient–physician communication. Therefore, this comprehensive care will improve their quality of life, treatment compliance, and general health care maintenance. This article offers innovative guidance to implement the post-cancer patient care and includes the relevant templates to be submitted to the patients. © 2016, Springer-Verlag France. Source


Demoor-Goldschmidt C.,Institute Of Cancerologie Of Louest | Bernier V.,Institute Of Cancerologie Of Lorraine
Bulletin du Cancer | Year: 2015

Pediatric radiotherapy did not differ technically from adult radiotherapy but its characteristics, its difficulties and challenges are specific. Thanks in part to this treatment, overall survival of French children with cancer is around 80%. It is therefore important to integrate in the elaboration of the treatment planning potential side long-term effects. Indeed, whatever the technique is, even the most sophisticated, it is usually inevitable that healthy nearby organs receive a dose of radiation. Dose limits on organs at risk come from adult data and are adapted for children. After the treatment, it is important to graduate the potential risks of side effects to propose a personalized monitoring protocol avoiding excessive medicalization. This article presents the medical thinking concerning radiotherapy in different anatomical areas (brain, head and neck, chest, abdomen) including concepts of dose level corresponding to side effects usually described. In parallel, we present follow-up recommendations with the aim to preserve an optimal quality of life for the adults cured of a childhood cancer, currently called survivors. © 2015 Société Française du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés. Source


The incidence of pancreatic adenocarcinoma doubled among men and tripled among women in 30 years. The majority of cases are metastatic at the diagnosis, making its dreadful short-term prognosis. Regarding the management of metastatic patients, chemotherapy alone, or in combination, is the only option. The challenge of management is to assess patients to offer optimal treatment, considering their expected tolerance. Gemcitabine, the standard treatment for many years, has gradually given way to Folfirinox for patients with a performance status of 0 or 1. One of the challenges of treating cancer is to have knowledge in choosing between Folfirinox and nab-paclitaxel plus gemcitabine as first-line treatment depending on the patients’ condition. Even though the second metastatic line is not yet well established, the nabpaclitaxel plus gemcitabine combination is very encouraging after Folfirinox. For the moment, erlotinib remains the only effective among targeted therapies, and it provides a modest contribution. The arrival of immunotherapies now focuses all hopes, in phase I or II studies with nivolumab, for example. © 2015, Springer-Verlag France. Source

Discover hidden collaborations